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ORIGINAL ARTICLE
U.S. prevalence of endocrine therapy–naïve 
locally advanced or metastatic breast cancer
A.P. Nunes phd,*† C. Liang phd,* W.J. Gradishar md,‡ T. Dalvi phd,§ J. Lewis phd,|| N. Jones bsc,||  
E. Green mph,* M. Doherty msc,* and J.D. Seeger drph*
ABSTRACT
Background Variations in treatment choice, or late stage at first diagnosis, mean that, despite guideline 
recommendations, not all patients with hormone receptor (hr)–positive locally advanced or metastatic breast 
cancer (la/mbca) will have received endocrine therapy before disease progression. In the present study, we aimed to 
estimate the proportion of women with postmenopausal hr-positive la/mbca in the United States who are endocrine 
therapy-naïve.
Methods Women in the Optum Electronic Health Record (ehr) database with a breast cancer (bca) diagnosis 
(January 2008–March 2015) were included. Patient and malignancy characteristics were identified using structured 
data fields and natural-language processing of free-text clinical notes. The proportion of women with postmenopausal 
hr-positive, human epidermal growth factor 2 (her2)–negative (or unknown) la/mbca who had not received prior 
endocrine therapy was determined. Results were extrapolated to the entire U.S. population using the U.S. National 
Cancer Institute’s Surveillance, Epidemiology, and End Results database. Results are presented descriptively.
Results In the ehr database, 11,831 women with bca had discernible information on postmenopausal status, hr 
status, and disease stage. Of those women, 1923 (16.3%) had postmenopausal hr-positive, her2-negative (or  unknown) 
la/mbca, and 70.7% of those 1923 patients (n = 1360) had not received prior endocrine therapy, accounting for 11.5% 
of the overall population. Extrapolating those estimates nationally suggests an annual incidence of 14,784 cases, and 
a 5-year limited duration prevalence of 50,638 cases.
Conclusions A substantial proportion of women with postmenopausal hr-positive la/mbca in the United States 
could be endocrine therapy–naïve.
Key Words Breast cancer, advanced; breast cancer, metastatic; electronic health records; endocrine therapy; 
hormone receptor–positive disease
Curr Oncol. 2019 April;26(2):e180-e187 www.current-oncology.com
INTRODUCTION
Most breast cancers (bcas) are hormone receptor (hr)–
positive [estrogen receptor (er)– or progesterone receptor 
(pgr)–positive, or both] and her2 (human epidermal growth 
factor 2)–negative at diagnosis1,2. Standard adjuvant treat-
ment for women with postmenopausal hr-positive bca 
includes endocrine therapy with tamoxifen or an aromatase 
inhibitor (letrozole, anastrozole, or exemestane)3–5. Fulves-
trant, a selective estrogen receptor degrader, was recently 
approved by the U.S. Food and Drug Administration for use 
in patients who have received no prior endocrine therapy6.
Because most bca is detected at an early stage, patients 
with postmenopausal hr-positive locally advanced or 
metastatic bca (la/mbca) are likely to have received prior 
endocrine therapy for their bca. Patients who have not re-
ceived prior endocrine therapy could include those with a 
primary diagnosis of la/mbca (that is, those patients who 
have not been treated for early bca), or less commonly, 
those with a previous diagnosis of early bca who, because 
of variability in real-world treatment decisions, did not 
receive adjuvant endocrine therapy.
Previous estimates of the size of the patient popula-
tion with a primary diagnosis of hr-positive advanced bca 
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have ranged from 13% to 17% of patients with a known hr 
status7–9. However, uncertainty about that estimate arises 
because of the limited generalizability of the findings of 
those small retrospective cohort studies. Understanding the 
prevalence of hr-positive advanced bca in patients not hav-
ing received prior endocrine therapy is important to confirm 
the extent to which newer treatments, such as fulvestrant, 
could address a treatment gap in patients with bca.
In the present study, we aimed to estimate the pro-
portion of patients in the United States with a diagnosis of 
postmenopausal hr-positive, her2-negative la/mbca who 
did not receive prior endocrine therapy (including patients 
with a primary diagnosis of hr-positive, her2-negative la/
mbca, and patients with prior early bca or la/mbca who did 
not receive prior endocrine therapy) and to extrapolate the 
findings to estimate the size of that population nationally.
METHODS
Study Population
This observational study relied on retrospectively ana-
lyzed data from the Optum Electronic Health Record (ehr) 
database, which documents patient care across various 
provider groups and health care settings in the United 
States, including approximately 43.3 million patients as of 
30 June 2014. As the data are sourced from multiple provider 
groups, they are converted into a consistent format before 
use. Information from structured fields within the ehr 
and through natural language processing (nlp) of free-text 
clinical notes was used, as previously reported10.
The cohort evaluated for the present study included 
women more than 40 years of age who had received a diag-
nosis of bca between 1 January 2008 and 31 March 2015. To 
reduce the number of false-positive cases identified, patients 
were required to have had at least 2 encounters with a bca di-
agnosis, coded according to the International Classification 
of Diseases (9th or 10th edition, or both), that were between 
30 and 180 days apart and to have at least 1 year of coverage 
in the ehr database (Figure 1). The index date was defined 
as the earliest date at which a patient met those criteria. A 
subset of that population was designated the target popula-
tion, defined as women with postmenopausal hr-positive, 
her2-negative (or unknown) la/mbca (Figure 1). Patients 
without a baseline prescription record and without at least 
1 physician office visit record in the 12 months before the 
index date were excluded to limit the population to patients 
with regular health care utilization within participating ehr 
systems and, therefore, to patients with a more complete 
record of health characteristics.
Patient characteristics (including demographics, ehr 
characteristics, health care utilization, and risk factors) 
were based on information obtained from encounters 
occurring in the baseline period of 12 months before and 
including the index date. Prior use of endocrine therapy 
and previous cancer diagnoses were defined in a baseline 
period of at least 12 months, but up to 5 years before the 
index date, when data were available. Prior use of endocrine 
therapy was determined using prescription data and med-
ication orders. Endocrine therapies included aromatase 
inhibitors, androgens, er antagonists, gonadotropin- 
releasing hormone agonists, gonadotropin-releasing 
hormone antagonists, luteinizing hormone–releasing 
agonists, and luteinizing hormone–releasing antagonists.
Postmenopausal status, hr status, her2 status, and 
cancer TNM stage were obtained from the nlp of free-text 
clinical notes within the ehrs. We used a generalized nlp 
approach that relied on feature-based context-free gram-
mar recognition developed specifically for clinical notes. 
That generalized approach is validated for the identifica-
tion of clinical concepts, features (for example, lists, tables, 
sentences), and grammar rules (used to provide sentiment 
and attributes of the clinical concepts). In women 40–55 
years of age, postmenopausal status was based on the pres-
ence of postmenopausal diagnostic codes or nlp-identified 
documentation of a patient’s postmenopausal status before 
the index date. Women more than 55 years of age were con-
sidered postmenopausal unless specifically contradicted 
by nlp-identified information in free-text notes. Hormone 
receptor status was described in terms of er or pgr status, 
or both. In addition to nlp-identified information from the 
free-text notes, hr status was established using Interna-
tional Classification of Diseases (9th edition) diagnostic 
codes and treatment history.
In our analysis, locally advanced bca was defined as 
a subset of stage iib (T3N0M0) and all stage iii disease. 
For the purpose of the guidelines developed at the Second 
International Consensus Guidelines for Advanced Breast 
Breast cancer cases
(with 1 year of encounter history)
Optum EHR (2008–2015)
(n = 63,962)
Mention of postmenopausal in the 
text and aged 40 years
(n = 49,871)
No mention of
postmenopausal in the text
or aged <40 years
(n = 14,091)
HR-positive 
(n = 23,392)
HR-negative 
(n = 2,001)
Uncertain
(n = 24,478)
HER2-positive
(n = 3,336)
Other or unknown stages
(n = 18,133)
HER2-negative or unknown
(n = 20,056)
Target population
Inoperable locally advanced or
metastatic cases  
(n = 1,923)
Incident cases
(n = 1,040)
Prevalent cases
(n = 883)
FIGURE 1 Flow chart for patient eligibility. EHR = electronic health 
record; HR = hormone receptor; HER2 = human epidermal growth 
factor receptor 2.
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Cancer11,12, the definition of locally advanced bca has been 
revised to include only inoperable locally advanced disease 
that has not yet spread to distant sites. Thus, for locally ad-
vanced malignancies, observed cases were excluded from 
the target population if a surgical procedure for mastectomy 
or lumpectomy occurred within 6 months of the diagnosis 
date. Metastatic bca was defined as cases meeting stage iv 
criteria. Cases were identified by using NLP to search the 
free-text notes to identify specific TNM stage and related 
attributes for BCa within the 6 months preceding and up 
to 6 months after the index date. As a supplement to TNM 
staging, we identified attributes of bca mentions that could 
be mapped to locally advanced or metastatic malignancies 
(for example, explicit mention of “metastatic” or “locally 
advanced” in the absence of TNM staging).
Diagnosis records—or records of chemotherapy, ra-
diotherapy, or endocrine therapy—were used to establish 
whether cases were considered primary la/mbca (that is, the 
first recorded diagnosis of cancer) or la/mbca with a prior 
bca diagnosis. Incident cases were defined as those with no 
evidence of a bca diagnosis, chemotherapy, or radiotherapy 
from a minimum of 12 months and up to 5 years before the 
index date. Individuals with evidence of a bca diagnosis, 
chemotherapy, or radiotherapy within 5 years before the 
index date were considered prevalent cases (recurrence of 
early bca or progression of la/mbca).
Data Analysis
To compare aspects of patient care in a variety of settings, 
estimates of the size of the target population were strati-
fied by region and year of diagnosis. Results are presented 
descriptively; no formal statistical comparisons are made.
Sensitivity analyses were performed to assess the 
influence of missing data on proportion estimates. Those 
analyses included patients with confirmed her2-negative 
status only, or with imputed values for missing hr status in 
the target population. Hormone receptor status was singly 
imputed, relying on a fully conditional specification with 
logistic imputation of er and pgr status. That imputation 
was performed using the SAS multiple imputation for miss-
ing data procedure (SAS Institute, Cary, NC, U.S.A.), with er 
and pgr status predicted based on all assessed covariates 
(patient characteristics comprising demographics, ehr 
characteristics, health care utilization, and risk factors). 
Assuming that the observed covariates explain differences 
between observed and missing values, a comparison of the 
original and imputed data tables allowed for quantification 
of bias attributable to missing data.
The proportion of the target population—patients with 
postmenopausal hr-positive, her2-negative (or unknown) 
la/mbca—in this sample who did not receive prior endo-
crine therapy was extrapolated using data from the U.S. 
National Cancer Institute’s Surveillance, Epidemiology, 
and End Results (seer) database to estimate the size of the 
target population at the national level13.
For prevalence estimates, the extrapolation approach 
multiplied the 2015 seer national estimate of 5-year prev-
alence (NSEER) by the seer estimate of the proportion of 
prevalent bcas for patients who were 55 years of age or older 
with hr-positive, her2-negative la/mbca (target popula-
tion, TPSEER) and by the observed ehr-based estimate of 
the proportion of prevalent cases in the target population 
without prior endocrine therapy (Untreated / TPEHR). 
Similarly, the incidence estimate multiplied the 2015 seer 
national estimate of bca cases by the seer estimate of the 
proportion of incident bca cases in the target population 
and by the observed ehr-based estimate of the proportion 
of the incident cases in the target population without prior 
hormone therapy:
Extrapolated N = NSEER × TPSEER × Untreated / TPEHR
RESULTS
Patient Populations
Overall, 63,962 women more than 40 years of age in the 
Optum ehr database were diagnosed with bca during the 
study period (Table i). Discernible information on post-
menopausal status, hr status, and disease stage (Table ii) 
was available for 11,831 patients. In all, the subset of pa-
tients with postmenopausal hr-positive, her2-negative (or 
unknown) la/mbca (the target population) comprised 1923 
patients. More than half those patients (54.1%, 1040 of 1923) 
had a primary diagnosis of la/mbca, and 45.9% (883 of 1923) 
had la/mbca after a prior bca diagnosis. Figure 2 compares 
the proportions of patients with a diagnosis of la/mbca or 
of early bca at the index date for incident cases (no prior bca 
diagnosis) and prevalent cases (with a prior bca diagnosis).
The target population tended to be older: only 3.4% of 
the target population (66 of 1923) was between 40 and 54 
years of age, compared with 22.2% of the overall cohort 
(14,189 of 63,962). In addition, compared with the overall 
cohort, the target population was more likely to have re-
ceived prior chemotherapy [10.2% (196 of 1923) vs. 4.7% 
(3019 of 63,962)].
Endocrine Therapy
Prior endocrine therapy had not been administered to 
70.7% of patients with postmenopausal hr-positive, 
her2-negative (or unknown) la/mbca [95% confidence 
interval (ci): 63.8% to 77.7%; 1360 of 1923]. Of patients in 
the target population without a record of prior bca, 88.5% 
(95% ci: 86.4% to 90.3%; 920 of 1040) had not received prior 
endocrine therapy within the 5 years preceding the index 
date. Among prevalent bca cases in the target population, 
49.8% (95% ci: 46.5% to 53.1%; 440 of 883) had no record 
of prior endocrine therapy. With imputation of missing 
hr status, those estimates were slightly higher: within the 
imputed target population, 91.1% of incident cases and 
77.2% of all cases had not received prior endocrine therapy.
Within the overall cohort, 11.5% of patients with bca and 
a discernible postmenopausal status, hr status, and disease 
stage (95% ci: 10.8% to 12.1%; 1360 of 11,831) satisfied the 
definition of the target population and had not received prior 
endocrine therapy. That proportion ranged from 8.5% in the 
South (95% ci: 7.5% to 9.5%; 299 of 3527) to 13.7% in the West 
(95% ci: 11.7% to 15.8%; 199 of 1448). Restricting the study 
population to incident cases with available postmenopausal 
status, hr status, and disease stage, the proportion of pa-
tients with a primary diagnosis of hr-positive, her2-negative 
(or unknown) la/mbca without prior endocrine therapy was 
16.2% (95% ci: 15.1% to 17.4%; 920 of 5671).
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A sensitivity analysis that imputed data for patients 
with missing hr information was performed. Of all eligible 
women with bca, the proportion of patients with postmeno-
pausal la/mbca, discernible hr status (imputed), and no 
prior endocrine therapy was 11.2% (95% ci: 10.7% to 11.8%; 
1624 of 14,448). That proportion declined to 6.7% (95% ci: 
6.3% to 7.2%; 798 of 11,831) when patients with unknown 
hr or her2 status were excluded from the target population.
Extrapolation to the U.S. Population
Extrapolation of the observed proportion of patients in this 
target population without prior endocrine therapy in the 
study sample to seer national estimates of patients with 
postmenopausal hr-positive, her2-negative la/mbca esti-
mated an annual incidence of 14,784 patients and a 5-year 
limited duration prevalence of 50,638 patients (Table iii).
DISCUSSION
The present study of real-world data provides an estimate of 
the number of patients with postmenopausal hr-positive, 
her2-negative (or unknown) la/mbca in the United States 
who have not received prior endocrine therapy.
Approximately half the patients in this study with a 
prior bca diagnosis (49.8%), and most without a prior bca 
diagnosis (88.5%), had not received endocrine therapy as 
of the study’s cohort entry date. Extrapolating those per-
centages to the U.S. population, we estimated an annual 
incidence of approximately 15,000 women with postmeno-
pausal hr-positive, her2-negative la/mbca who have not 
received prior endocrine therapy.
Sensitivity analyses were conducted to assess the 
potential effect of missing hr status data (imputation of 
missing values) and unknown her2 status (exclusion of 
patients with uncertain values). Relative to analyses of 
patients with a known hr or her2 status, analyses with im-
puted values for missing hr status yielded a higher estimate 
of the proportion of the overall bca population who met 
the definition for the untreated target population. Given 
that her2 status was unknown for a large proportion of the 
patients (69.5%), excluding those patients (a proportion of 
whom would have been her2-negative) without changing 
the denominator represents the lower bound of the estimate 
with her2-negative cases. However, we did not observe a 
notable difference in the estimate of the proportion of the 
target population without prior endocrine therapy in the 
analyses with and without imputation (77.2% vs. 75.9% 
respectively). Consequently, the national extrapolations 
are expected to be minimally affected by biases resulting 
from missing hr or her2 status within the ehr database.
TABLE I Baseline demographic characteristics of women diagnosed with hormone receptor–positive, HER2-negative (or unknown) locally advanced 
or metastatic breast cancera
Variable Patients  
Overall
(n=63,962)
Target
group
(n=1,923)
Incident cases, target group 
Endocrine therapy
Prevalent cases, target group 
Endocrine therapy
Yes
(n=920)
No
(n=120)
Yes
(n=440)
No
(n=443)
Age group [n (%)]
40–44 Years 3,123 (4.9) 10 (0.5) 3 (0.3) 0 (0.0) 4 (0.9) 3 (0.7)
45–54 Years 11,066 (17.3) 56 (2.9) 38 (4.1) 1 (0.8) 11 (2.5) 6 (1.4)
55–64 Years 16,333 (25.5) 663 (34.5) 313 (34.0) 38 (31.7) 154 (35.0) 158 (35.7)
65–74 Years 17,879 (28.0) 694 (36.1) 323 (35.1) 44 (36.7) 160 (36.4) 167 (37.7)
75–84 Years 12,561 (19.6) 395 (20.5) 185 (20.1) 27 (22.5) 89 (20.2) 94 (21.2)
≥85 Years 3,000 (4.7) 105 (5.5) 58 (6.3) 10 (8.3) 22 (5.0) 15 (3.4)
Race or ethnicity [n (%)]
White or non-Hispanic 53,173 (83.1) 1,620 (84.2) 775 (84.2) 99 (82.5) 371 (84.3) 375 (84.7)
Black or non-Hispanic 4,036 (6.3) 140 (7.3) 72 (7.8) 11 (9.2) 31 (7.0) 26 (5.9)
Hispanic 1,892 (3.0) 40 (2.1) 21 (2.3) 1 (0.8) 11 (2.5) 7 (1.6)
Asian or Pacific Islander 1,458 (2.3) 25 (1.3) 13 (1.4) 0 (0.0) 4 (0.9) 8 (1.8)
Multiple races 1,110 (1.7) 39 (2.0) 22 (2.4) 2 (1.7) 9 (2.0) 6 (1.4)
Unknown 2,293 (3.6) 59 (3.1) 17 (1.8) 7 (5.8) 14 (3.2) 21 (4.7)
U.S. geographic regionb [n (%)]
Northeast 11,449 (17.9) 217 (11.3) 116 (12.6) 7 (5.8) 50 (11.4) 44 (9.9)
Midwest 26,183 (40.9) 975 (50.7) 495 (53.8) 56 (46.7) 201 (45.7) 223 (50.3)
South 16,916 (26.4) 428 (22.3) 185 (20.1) 42 (35.0) 114 (25.9) 87 (19.6)
West 9,412 (14.7) 303 (15.8) 124 (13.5) 15 (12.5) 75 (17.0) 89 (20.1)
a  Optum electronic health record database, 1 January 2008 to 31 March 2015.
b Unknown for 2 patients.
HER2 = human epidermal growth factor receptor 2.
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TABLE II Disease characteristics for the overall breast cancer study cohort
Characteristic Incident cases
(n=35,600)
Prevalent cases
(n=28,362)
All cases
(n=63,962)
Postmenopausal status
Yes 27,707 (77.8) 22,164 (78.1) 49,871 (78.0)
No 7,893 (22.2) 6,198 (21.9) 14,091 (22.0)
Hormone receptor status
ER-positive, PgR-positive 12,072 (33.9) 5,515 (19.4) 17,587 (27.5)
ER-positive, PgR-negative 1,406 (3.9) 726 (2.6) 2,132 (3.3)
ER-positive, PgR uncertain 1,599 (4.5) 1,221 (4.3) 2,820 (4.4)
ER-negative, PgR-positive 444 (1.2) 89 (0.3) 533 (0.8)
ER-negative, PgR-negative 2,025 (5.7) 1,154 (4.1) 3,179 (5.0)
ER-negative, PgR uncertain 328 (0.9) 207 (0.7) 535 (0.8)
ER uncertain, PgR-positive 1,075 (3.0) 497 (1.8) 1,572 (2.5)
ER uncertain, PgR-negative 325 (0.9) 215 (0.8) 540 (0.8)
Missing or uncertain 16,326 (45.9) 18,738 (66.1) 35,064 (54.8)
HER2 status
Positive 4,606 (12.9) 1,931 (6.8) 6,537 (10.2)
Negative 8,559 (24.0) 4,392 (15.5) 12,951 (20.2)
Uncertain 22,435 (63.0) 22,039 (77.7) 44,474 (69.5)
Disease stage at index date
Early 14,005 (39.3) 7,298 (25.7) 21,303 (33.3)
Locally advanced 2,202 (6.2) 1,858 (6.6) 4,060 (6.3)
Metastatic 559 (1.6) 639 (2.3) 1,198 (1.9)
Uncertain 18,834 (52.9) 18,567 (65.5) 37,401 (58.5)
First time diagnosed as locally advanced or metastatic
Yes 713 (2.0) 1,801 (6.4) 2,514 (3.9)
No 3,201 (9.0) 4,936 (17.4) 8,137 (12.7)
Uncertain 31,686 (89.0) 21,625 (76.2) 53,311 (83.4)
Prior endocrine therapy
Yes 1,870 (5.3) 5,774 (20.4) 7,644 (12.0)
No 33,730 (94.7) 22,588 (79.6) 56,318 (88.0)
ER = estrogen receptor; PgR = progesterone receptor; HER2 = human epidermal growth factor receptor 2.
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FIGURE 2 Proportion of patients with breast cancer by primary diagnosis. EHR = electronic health record.
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Despite treatment guidelines3–5,14,15, many patients 
with prevalent hr-positive, her2-negative (or unknown) 
la/mbca had not received prior endocrine therapy. Reasons 
for that observation might include prescriber preference for 
treatments such as chemotherapy or radiotherapy (or both) 
over endocrine therapy or a consideration that the risk of 
recurrence was sufficiently low in some patients to offset 
the potential side effects of adjuvant endocrine therapy. 
In an analysis of patients with hr-positive advanced bca, 
Bonotto et al.16 determined that 38% of patients received 
first-line chemotherapy instead of endocrine therapy, with 
the choice being driven by age and site of metastases (endo-
crine therapy was preferentially provided to older patients, 
and in the case of bone metastases only). Patient preference 
and contraindications might also be contributing factors. 
In addition, it is possible that the ehr data might have un-
derestimated the number of patients who received prior 
endocrine therapy. The median baseline period available 
for patients within this ehr-based cohort was 3.2 years. 
Because the median recurrence-free survival time for bca 
is approximately 3.5 years17, prior endocrine therapy for 
early bca outside the limit of our study might not have been 
captured. Furthermore, patients could have relocated and 
received care at nonparticipating institutions, where the 
treatment received would have been unknown.
It could be expected that, in all incident cases of bca, 
patients wouldnot have received prior endocrine therapy. 
However, 11.5% of incident cases of la/mbca in the present 
study had a record of prior endocrine therapy. It is possible 
that some patients in the study were prescribed endocrine 
therapy for prevention rather than for treatment of bca. 
For example, in the present study, raloxifene (generally 
used for prevention of bca) was used in 14.2% of patients 
with incident hr-positive la/mbca who had received prior 
endocrine therapy. In addition, as mentioned previously, 
endocrine therapy might have been recorded for cancer 
diagnoses that were outside the available capture of ehr 
encounters in the study database and thus might actually 
reflect endocrine therapy for prevalent patients.
The results of the present study are specific to the Unit-
ed States; however, the same patient population might be 
common in developing countries, where patients are more 
likely to present with advanced bca18. Furthermore, this 
patient population might be more relevant to community 
practices (where patients are more likely to receive initial 
diagnosis and treatment) than to specialist referral centres, 
where encountering such patients could be less likely.
The observed distributions of disease stage and hr 
status in the present study were largely consistent with 
seer-published values, although they were sometimes 
higher than expected. The proportion of la/mbca cases in 
this ehr sample was 16.5% of incident cases with discern-
ible status (2761 of 16,766); in comparison, approximately 
13% of incident bca cases were identified as stage iii or iv 
within the 2010 seer data19. However, it could be expected 
that the seer and ehr estimates are not identical, given 
that some cases of stage iib bca were included in the ehr-
based estimate, but not in the seer estimate. In addition, 
the proportion of patients receiving a primary diagnosis of 
la/mbca in our study was similar (18.2%) to that in other 
published real-world-evidence studies7–9,20.
According to the American Cancer Society, 84% of bca 
is hr-positive1. When the present study took into account 
diagnostic codes, prior hormonal treatment, and nlp of 
free-text clinical notes, hr-positive status was reported for 
91% of patients. That increased proportion might reflect 
recording practices in ehr data systems. For instance, 
clinicians might be more likely to record positive than 
negative hr status or advanced-stage results within free 
notes, which would then influence the denominator in the 
calculation of prevalence. Alternatively, the distribution 
of hr status varies by patient characteristics, with higher 
TABLE III Extrapolated numbers for cases of postmenopausal hormone receptor–positive (HR+), HER2-negative (HER2–) locally advanced or 
metastatic breast cancer (LA/mBCa) without prior endocrine therapy (“target occurrence”)
Variable Estimate
Incidence Prevalence
SEER estimatesa
National HR+, HER2– LA/mBCa occurrence (n) 231,840 1,171,300
In patients ≥55 years of age (%) 7.0 5.6
National postmenopausal HR+, HER2– LA/mBCa occurrence (n) 16,229 65,593
(231,840×7.0%) (1,171,300×5.6%)
Extrapolationb
Incidence Prevalence
Target occurrence based on imputed hormone receptor data
14,784 
(16,229×91.1%)
50,638 
(65,593×77.2%)
a  SEER*Stat Database: SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, released April 2016, based on the November 
2015 submission (full reference available upon request).
b  Based on the estimate from SEER, multiplied by the untreated percentage of the postmenopausal HR+, HER2– LA/mBCa population in the Optum 
electronic health record database, 1 January 2008 to 31 March 2015.
HER2 = human epidermal growth factor receptor 2; SEER = Surveillance, Epidemiology, and End Results program.
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rates of er-positive bca in older patient populations than 
in younger patient populations21,22, and thus the elevat-
ed estimate of hr-positive bca in the ehr data might be 
attributable, in part, to the focus of our study on a post-
menopausal patient population.
Interpretation of our study results is subject to certain 
limitations. Data residing in ehr systems are intended to 
document patient care and to ensure continuity of infor-
mation across providers and are not designed for research 
purposes. As a result, those data should be interpreted with 
caution and recognition of what they represent. A large 
number of providers in the United States are not included 
in the Optum ehr database, and furthermore, patient care 
received through encounters with health care providers out-
side the Optum ehr systems would be captured only when 
documented in the notes of participating provider systems.
The incident cases identified in the present study 
might not necessarily be newly diagnosed cases, because 
inclusion in the study was based on the time of a patient’s 
earliest qualifying diagnosis. Accordingly, incident cases 
are likely to be somewhat overestimated in the Optum ehr 
cohort compared with the seer database, and the results 
of the extrapolation calculations should therefore be inter-
preted with that potential in mind.
Several recent publications have presented efficacy 
and safety data from phase iii randomized trials evaluating 
various treatments in this patient population (postmeno-
pausal hr-positive la/mbca without prior endocrine therapy). 
Fulvestrant is a selective er degrader that is currently 
approved as monotherapy, or in combination with the 
cyclin-dependent kinase 4/6 inhibitor palbociclib, for the 
treatment of hr-positive, her2-negative la/mbca in post-
menopausal women with disease progression after prior 
endocrine therapy23. Results of the recently completed 
phase iii falcon study24 (NCT01602380 at http://Clinical 
Trials.gov/) indicated that fulvestrant monotherapy 
(500 mg) was superior to anastrozole as first-line treatment 
for hr-positive la/mbca in patients who had received no 
prior endocrine therapy. Fulvestrant was recently approved 
by the U.S. Food and Drug Administration for use in that 
patient population6. The falcon trial included women with 
confirmed hr-positive la/mbca who had not received 
prior hormonal treatment for bca. The trial was restricted 
to patients with a World Health Organization performance 
status of 0–2, one or more measurable or non-measurable 
lesions, and no life-threatening metastatic visceral disease; 
further restrictions were also placed on receipt of prior 
therapies for bca. Results of the present real-world evidence 
study have defined the size of the patient population to whom 
the results of the falcon study would be most applicable.
Fu r t her more, paloma-225 (NCT01740427) a nd 
monaleesa-226 (NCT01958021) demonstrated that the 
combination of a cyclin-dependent kinase 4/6 inhibitor 
(palbociclib and ribociclib respectively) with letrozole was 
more effective than letrozole alone as first-line treatment 
for hr-positive la/mbca. Although patients could have 
received prior adjuvant endocrine therapy, both studies 
included a substantial proportion of patients who had not 
received prior endocrine therapy (43.7% and 48.2% respec-
tively). A consistent treatment effect was observed between 
the subgroups with and without prior endocrine therapy.
It is important to note that, to optimize outcomes, 
decisions about treatment should be made on an indi-
vidual patient basis. Based on recent data, monotherapy 
with fulvestrant could be considered for the patient 
population described in the present study. Endocrine 
therapy in combination with a targeted treatment such as 
a cyclin-dependent kinase 4/6 inhibitor could also be an 
option in patients for whom those therapies are available.
CONCLUSIONS
In the present study, we have defined the specific popu-
lation of patients who have not received prior endocrine 
therapy, which represents a significant proportion of pa-
tients with postmenopausal hr-positive la/mbca in the 
United States.
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